Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-positive AML Defines Novel Therapeutic Options - A COG and TARGET Pediatric AML Study.

Smith JL, Ries RE, Hylkema T, Alonzo TA, Gerbing RB, Santaguida MT, Eidenschink Brodersen L, Pardo L, Cummings CL, Loeb KR, Le Q, Imren S, Leonti AR, Gamis AS, Aplenc R, Kolb EA, Farrar JE, Triche TJ, Nguyen C, Meerzaman D, Loken MR, Oehler VG, Bolouri H, Meshinchi S.

Clin Cancer Res. 2019 Nov 12. pii: clincanres.1800.2019. doi: 10.1158/1078-0432.CCR-19-1800. [Epub ahead of print]

PMID:
31719049
2.

Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.

Pardo LM, Voigt AP, Alonzo TA, Wilson ER, Gerbing RB, Paine DJ, Dai F, Menssen AJ, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Wells DA, Brodersen LE, Loken MR.

Cytometry B Clin Cytom. 2019 Jul 11. doi: 10.1002/cyto.b.21829. [Epub ahead of print]

PMID:
31294507
3.

Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia.

Tarlock K, Alonzo TA, Wang YC, Gerbing RB, Ries R, Loken MR, Pardo L, Hylkema T, Joaquin J, Sarukkai L, Raimondi SC, Hirsch B, Sung L, Aplenc R, Bernstein I, Gamis AS, Meshinchi S, Pollard JA.

Clin Cancer Res. 2019 Aug 15;25(16):5038-5048. doi: 10.1158/1078-0432.CCR-18-1897. Epub 2019 Jun 10.

PMID:
31182436
4.

Evidence for BCR/ABL1-positive T-cell acute lymphoblastic leukemia arising in an early lymphoid progenitor cell.

Ragg S, Zehentner BK, Loken MR, Croop JM.

Pediatr Blood Cancer. 2019 Sep;66(9):e27829. doi: 10.1002/pbc.27829. Epub 2019 May 28.

PMID:
31136068
5.

ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial.

Rafiee R, Chauhan L, Alonzo TA, Wang YC, Elmasry A, Loken MR, Pollard J, Aplenc R, Raimondi S, Hirsch BA, Bernstein ID, Gamis AS, Meshinchi S, Lamba JK.

Blood Cancer J. 2019 May 21;9(6):51. doi: 10.1038/s41408-019-0211-y.

6.

CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents.

Papageorgiou I, Loken MR, Brodersen LE, Gbadamosi M, Uy GL, Meshinchi S, Lamba JK.

Leuk Lymphoma. 2019 Sep;60(9):2287-2290. doi: 10.1080/10428194.2019.1569232. Epub 2019 Feb 5. No abstract available.

PMID:
30721105
7.

Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression.

Jacobsohn DA, Loken MR, Fei M, Adams A, Brodersen LE, Logan BR, Ahn KW, Shaw BE, Kletzel M, Olszewski M, Khan S, Meshinchi S, Keating A, Harris A, Teira P, Duerst RE, Margossian SP, Martin PL, Petrovic A, Dvorak CC, Nemecek ER, Boyer MW, Chen AR, Davis JH, Shenoy S, Savasan S, Hudspeth MP, Adams RH, Lewis VA, Kheradpour A, Kasow KA, Gillio AP, Haight AE, Bhatia M, Bambach BJ, Haines HL, Quigg TC, Greiner RJ, Talano JM, Delgado DC, Cheerva A, Gowda M, Ahuja S, Ozkaynak M, Mitchell D, Schultz KR, Fry TJ, Loeb DM, Pulsipher MA.

Biol Blood Marrow Transplant. 2018 Oct;24(10):2040-2046. doi: 10.1016/j.bbmt.2018.06.010. Epub 2018 Jun 19.

8.

CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients.

Lamba JK, Voigt AP, Chauhan L, Shin M, Aplenc R, Eidenschink Brodersen L, Gamis AS, Meshinchi S, Loken MR.

Leuk Lymphoma. 2018 Sep;59(9):2250-2253. doi: 10.1080/10428194.2017.1421756. Epub 2018 Jan 10. No abstract available.

PMID:
29320902
9.

Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531.

Voigt AP, Brodersen LE, Alonzo TA, Gerbing RB, Menssen AJ, Wilson ER, Kahwash S, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Wells DA, Loken MR.

Haematologica. 2017 Dec;102(12):2058-2068. doi: 10.3324/haematol.2017.169029. Epub 2017 Sep 7.

10.

Acute Myeloid Leukemia with RAM Immunophenotype: A Pediatric Case with Unusual Morphologic Features.

Conces M, Abu-Arja R, Reed S, Rangarajan HG, Guinipero TL, Loken MR, Brodersen LE, Kahwash SB.

Hematol Rep. 2017 Jun 14;9(2):7057. doi: 10.4081/hr.2017.7057. eCollection 2017 Jun 1.

11.

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.

Lamba JK, Chauhan L, Shin M, Loken MR, Pollard JA, Wang YC, Ries RE, Aplenc R, Hirsch BA, Raimondi SC, Walter RB, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S.

J Clin Oncol. 2017 Aug 10;35(23):2674-2682. doi: 10.1200/JCO.2016.71.2513. Epub 2017 Jun 23.

12.

Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.

Tarlock K, Alonzo TA, Loken MR, Gerbing RB, Ries RE, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash SB, McKenney A, Kolb EA, Gamis AS, Meshinchi S.

Clin Cancer Res. 2017 Jul 15;23(14):3649-3656. doi: 10.1158/1078-0432.CCR-16-2353. Epub 2017 Jan 20.

13.

Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.

Burnworth B, Wang Z, Singleton TP, Bennington A, Fritschle W, Bennington R, Brodersen LE, Wells DA, Loken MR, Zehentner BK.

Leuk Res. 2016 Dec;51:41-48. doi: 10.1016/j.leukres.2016.10.008. Epub 2016 Oct 18.

PMID:
27890075
14.

Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.

Westers TM, Cremers EM, Oelschlaegel U, Johansson U, Bettelheim P, Matarraz S, Orfao A, Moshaver B, Brodersen LE, Loken MR, Wells DA, Subirá D, Cullen M, Te Marvelde JG, van der Velden VH, Preijers FW, Chu SC, Feuillard J, Guérin E, Psarra K, Porwit A, Saft L, Ireland R, Milne T, Béné MC, Witte BI, Della Porta MG, Kern W, van de Loosdrecht AA; IMDSFlow Working Group.

Haematologica. 2017 Feb;102(2):308-319. doi: 10.3324/haematol.2016.147835. Epub 2016 Oct 6.

15.

miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.

Ramamurthy R, Hughes M, Morris V, Bolouri H, Gerbing RB, Wang YC, Loken MR, Raimondi SC, Hirsch BA, Gamis AS, Oehler VG, Alonzo TA, Meshinchi S.

Pediatr Blood Cancer. 2016 Dec;63(12):2096-2103. doi: 10.1002/pbc.26157. Epub 2016 Aug 11.

16.

Consistent quantitative gene product expression: #3. Invariance with age.

Loken MR, Voigt AP, Eidenschink Brodersen L, Fritschle W, Menssen AJ, Wells DA.

Cytometry A. 2016 Nov;89(11):997-1000. doi: 10.1002/cyto.a.22997. Epub 2016 Oct 18.

17.

Consistent quantitative gene product expression: #2. Antigen intensities on bone marrow cells are invariant between individuals.

Loken MR, Voigt AP, Eidenschink Brodersen L, Fritschle W, Menssen AJ, Meshinchi S, Wells DA.

Cytometry A. 2016 Nov;89(11):987-996. doi: 10.1002/cyto.a.22999. Epub 2016 Oct 18.

18.

Consistent quantitative gene product expression: #1. Automated identification of regenerating bone marrow cell populations using support vector machines.

Voigt AP, Eidenschink Brodersen L, Pardo L, Meshinchi S, Loken MR.

Cytometry A. 2016 Nov;89(11):978-986. doi: 10.1002/cyto.a.22905. Epub 2016 Jul 14.

19.

A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children's Oncology Group.

Eidenschink Brodersen L, Alonzo TA, Menssen AJ, Gerbing RB, Pardo L, Voigt AP, Kahwash SB, Hirsch B, Raimondi S, Gamis AS, Meshinchi S, Loken MR.

Leukemia. 2016 Oct;30(10):2077-2080. doi: 10.1038/leu.2016.119. Epub 2016 May 2. No abstract available.

20.

Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.

Tarlock K, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis AS, Meshinchi S.

Clin Cancer Res. 2016 Apr 15;22(8):1951-7. doi: 10.1158/1078-0432.CCR-15-1349. Epub 2015 Dec 7.

21.

Promyelocytic Leukemia with No Retinoic Acid Receptor Alpha Abnormality but with RUNX1T1 Insertion to Chromosome 7q: A Classification and Management Dilemma.

Overholt K, Guinipero TL, Heerema NA, Loken MR, Kahwash SB.

Case Rep Hematol. 2015;2015:412016. doi: 10.1155/2015/412016. Epub 2015 Aug 17.

22.

Assessment of erythroid dysplasia by "difference from normal" in routine clinical flow cytometry workup.

Eidenschink Brodersen L, Menssen AJ, Wangen JR, Stephenson CF, de Baca ME, Zehentner BK, Wells DA, Loken MR.

Cytometry B Clin Cytom. 2015 Mar;88(2):125-35. doi: 10.1002/cyto.b.21199. Epub 2014 Dec 10.

23.

Assessment of erythroid dysplasia by "difference from normal" in routine clinical flow cytometry work-up.

Eidenschink Brodersen L, Menssen AJ, Wangen JR, Stephenson CF, de Baca ME, Zehentner BK, Wells DA, Loken MR.

Cytometry B Clin Cytom. 2014 Oct 21. doi: 10.1002/cytob.21199. [Epub ahead of print]

24.

Detection of clonal evolution in hematopoietic malignancies by combining comparative genomic hybridization and single nucleotide polymorphism arrays.

Hartmann L, Stephenson CF, Verkamp SR, Johnson KR, Burnworth B, Hammock K, Brodersen LE, de Baca ME, Wells DA, Loken MR, Zehentner BK.

Clin Chem. 2014 Dec;60(12):1558-68. doi: 10.1373/clinchem.2014.227785. Epub 2014 Oct 15.

25.

NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report.

Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, Lange BJ, Petersdorf S, Radich J, Appelbaum FR, Gamis AS, Alonzo TA, Meshinchi S.

Blood. 2014 Oct 9;124(15):2400-7. doi: 10.1182/blood-2014-04-570929. Epub 2014 Aug 21.

26.

AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.

Cooper TM, Alonzo TA, Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, Horton TM, Gamis AS, Meshinchi S, Loken MR, Razzouk BI.

Cancer. 2014 Aug 15;120(16):2482-9. doi: 10.1002/cncr.28674. Epub 2014 Apr 25.

27.

Prognostic significance of flow cytometric residual disease, dysregulated neutrophils/monocytes, and hematogones in adult acute myeloid leukemia in first remission.

Chu SC, Wang TF, Su YC, Kao RH, Wu YF, Li DK, Li SC, Li CC, Wells DA, Loken MR.

Int J Hematol. 2014 Mar;99(3):296-304. doi: 10.1007/s12185-014-1525-y. Epub 2014 Jan 31.

PMID:
24481944
28.

Residual disease in AML, a target that can move in more than one direction.

Loken MR.

Cytometry B Clin Cytom. 2014 Jan;86(1):15-7. doi: 10.1002/cyto.b.21140. Epub 2013 Nov 15. No abstract available.

29.

Residual disease in AML, a target that can move in more than one direction.

Loken MR.

Cytometry B Clin Cytom. 2013 Oct 26. doi: 10.1002/cytob.21140. [Epub ahead of print] No abstract available.

30.

Assessment of normal erythropoiesis by flow cytometry: important considerations for specimen preparation.

Wangen JR, Eidenschink Brodersen L, Stolk TT, Wells DA, Loken MR.

Int J Lab Hematol. 2014 Apr;36(2):184-96. doi: 10.1111/ijlh.12151. Epub 2013 Oct 3.

PMID:
24118926
31.

Intraclonal heterogeneity in concomitant monoclonal lymphocyte and plasma cell populations: combining flow cytometric cell sorting with molecular monoclonality profiling.

Zehentner BK, de Baca ME, Wells DA, Loken MR.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):214-7. doi: 10.1016/j.clml.2013.02.004. Epub 2013 Mar 13.

PMID:
23490988
32.

Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy.

Mortland L, Alonzo TA, Walter RB, Gerbing RB, Mitra AK, Pollard JA, Loken MR, Hirsch B, Raimondi S, Franklin J, Pounds S, Cao X, Rubnitz JE, Ribeiro RC, Gamis A, Meshinchi S, Lamba JK.

Clin Cancer Res. 2013 Mar 15;19(6):1620-7. doi: 10.1158/1078-0432.CCR-12-3115. Epub 2013 Feb 26.

33.

Array-based karyotyping in plasma cell neoplasia after plasma cell enrichment increases detection of genomic aberrations.

Zehentner BK, Hartmann L, Johnson KR, Stephenson CF, Chapman DB, de Baca ME, Wells DA, Loken MR, Tirtorahardjo B, Gunn SR, Lim L.

Am J Clin Pathol. 2012 Oct;138(4):579-89.

PMID:
23010713
34.

Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.

van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, Bettelheim P, Bowen DT, Burbury K, Eidenschink L, Cazzola M, Chu SS, Cullen M, Cutler JA, Dräger AM, Feuillard J, Fenaux P, Font P, Germing U, Haase D, Hellström-Lindberg E, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Nikolova V, Ogata K, Oelschlaegel U, Orfao A, Ossenkoppele GJ, Porwit A, Platzbecker U, Preijers F, Psarra K, Richards SJ, Subirá D, Seymour JF, Tindell V, Vallespi T, Valent P, van der Velden VH, Wells DA, de Witte TM, Zettl F, Béné MC, Westers TM.

Leuk Lymphoma. 2013 Mar;54(3):472-5. doi: 10.3109/10428194.2012.718341. Epub 2012 Sep 14. Review.

PMID:
22916713
35.

Response to "Severe pernicious anemia with distinct cytogenetic and flow cytometric aberrations mimicking myelodysplastic syndrome".

Wells DA, Loken MR.

Ann Hematol. 2012 Dec;91(12):1983. doi: 10.1007/s00277-012-1504-4. Epub 2012 Jun 16. No abstract available.

PMID:
22706670
36.

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.

Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, Ho PA, Franklin J, Cooper TM, Gamis AS, Meshinchi S.

Blood. 2012 Aug 23;120(8):1581-8. doi: 10.1182/blood-2012-02-408336. Epub 2012 May 30.

37.

Somatic mutations in the HLA genes of patients with hematological malignancy.

Smith AG, Fan W, Regen L, Warnock S, Sprague M, Williams R, Nisperos B, Zhao LP, Loken MR, Hansen JA, Pereira S.

Tissue Antigens. 2012 May;79(5):359-66. doi: 10.1111/j.1399-0039.2012.01868.x.

PMID:
22489945
38.

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group.

Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, Burbury K, Cullen M, Cutler JA, Della Porta MG, Dräger AM, Feuillard J, Font P, Germing U, Haase D, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Ogata K, Orfao A, Porwit A, Psarra K, Richards SJ, Subirá D, Tindell V, Vallespi T, Valent P, van der Velden VH, de Witte TM, Wells DA, Zettl F, Béné MC, van de Loosdrecht AA.

Leukemia. 2012 Jul;26(7):1730-41. doi: 10.1038/leu.2012.30. Epub 2012 Feb 6.

PMID:
22307178
39.

Detection of genomic abnormalities in multiple myeloma: the application of FISH analysis in combination with various plasma cell enrichment techniques.

Hartmann L, Biggerstaff JS, Chapman DB, Scott JM, Johnson KR, Ghirardelli KM, Fritschle WK, Martinez DL, Bennington RK, de Baca ME, Wells DA, Loken MR, Zehentner BK.

Am J Clin Pathol. 2011 Nov;136(5):712-20. doi: 10.1309/AJCPF7NFLW8UAJEP.

PMID:
22031309
40.

Basal levels of CD34 positive cells in peripheral blood differ between individuals and are stable for 18 months.

Eidenschink L, DiZerega G, Rodgers K, Bartlett M, Wells DA, Loken MR.

Cytometry B Clin Cytom. 2012 Jan;82(1):18-25. doi: 10.1002/cyto.b.20611. Epub 2011 Aug 2.

41.

A minority of concurrent monoclonal lymphocytes and plasmacytic cells sharing light chains are genetically related in putative lymphoplasmacytic lymphoma.

Zehentner BK, Cutler JA, Fritschle WK, Bennington RK, Wentzel C, Smading SR, Jeffery EW, Wells DA, Loken MR.

Leuk Res. 2011 Dec;35(12):1597-604. doi: 10.1016/j.leukres.2011.06.012. Epub 2011 Jul 14.

PMID:
21752465
42.

Phenotypic abnormalities strongly reflect genotype in patients with unexplained cytopenias.

Cutler JA, Wells DA, van de Loosdrecht AA, de Baca ME, Kalnoski MH, Zehentner BK, Eidenschink L, Ghirardelli KM, Biggerstaff JS, Loken MR.

Cytometry B Clin Cytom. 2011 May;80(3):150-7. doi: 10.1002/cyto.b.20582. Epub 2010 Dec 23.

43.

Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes.

Chu SC, Wang TF, Li CC, Kao RH, Li DK, Su YC, Wells DA, Loken MR.

Leuk Res. 2011 Jul;35(7):868-73. doi: 10.1016/j.leukres.2011.02.016. Epub 2011 Mar 12.

PMID:
21397943
44.

Minimal residual disease detected prior to hematopoietic cell transplantation.

Foster JH, Hawkins DS, Loken MR, Wells DA, Thomson B.

Pediatr Blood Cancer. 2011 Jul 15;57(1):163-5. doi: 10.1002/pbc.23079. Epub 2011 Mar 2.

PMID:
21370437
45.

High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group.

Walter RB, Alonzo TA, Gerbing RB, Ho PA, Smith FO, Raimondi SC, Hirsch BA, Gamis AS, Franklin JL, Hurwitz CA, Loken MR, Meshinchi S.

J Clin Oncol. 2010 Jun 10;28(17):2831-8. doi: 10.1200/JCO.2009.27.5693. Epub 2010 Apr 26.

46.

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.

van de Loosdrecht AA, Alhan C, Béné MC, Della Porta MG, Dräger AM, Feuillard J, Font P, Germing U, Haase D, Homburg CH, Ireland R, Jansen JH, Kern W, Malcovati L, Te Marvelde JG, Mufti GJ, Ogata K, Orfao A, Ossenkoppele GJ, Porwit A, Preijers FW, Richards SJ, Schuurhuis GJ, Subirá D, Valent P, van der Velden VH, Vyas P, Westra AH, de Witte TM, Wells DA, Loken MR, Westers TM.

Haematologica. 2009 Aug;94(8):1124-34. doi: 10.3324/haematol.2009.005801. Epub 2009 Jun 22.

47.

The role of flow cytometry in myelodysplastic syndromes.

Loken MR, Wells DA.

J Natl Compr Canc Netw. 2008 Oct;6(9):935-41.

PMID:
18926102
48.

Multidimensional data analysis in immunophenotyping.

Loken MR.

Curr Protoc Cytom. 2001 May;Chapter 10:Unit 10.4. doi: 10.1002/0471142956.cy1004s00.

PMID:
18770678
49.

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome.

Scott BL, Wells DA, Loken MR, Myerson D, Leisenring WM, Deeg HJ.

Blood. 2008 Oct 1;112(7):2681-6. doi: 10.1182/blood-2008-05-153700. Epub 2008 Jul 7.

50.

Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses.

Loken MR, Chu SC, Fritschle W, Kalnoski M, Wells DA.

Cytometry B Clin Cytom. 2009 Jan;76(1):27-36. doi: 10.1002/cyto.b.20429. Epub 2008 Jun 11.

Supplemental Content

Loading ...
Support Center